Literature DB >> 10470478

Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area.

L Faber1, H Seggewiss, P Ziemssen, U Gleichmann.   

Abstract

Percutaneous transluminal septal myocardial ablation (PTSMA) has been introduced as an alternative to surgery for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Visualization of the ablation area prior to induction of the chemical necrosis is possible by intraprocedural myocardial contrast echocardiography (MCE). We report on two patients in whom MCE showed opacification of the medial papillary muscle or the left ventricular posterolateral free wall. In both patients the correct ablation area could be identified by MCE after a change of the target vessel, thus avoiding potentially fatal complications due to induction of a necrosis of myocardium distant from the septal target area.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470478     DOI: 10.1002/(SICI)1522-726X(199908)47:4<462::AID-CCD16>3.0.CO;2-9

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 2.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

4.  Serial septal branch assessment in hypertrophic obstructive cardiomyopathy: New echocardiographic contrast agent for alcohol septal ablation.

Authors:  A G Rigopoulos; B Pfeiffer; H Seggewiss
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

5.  Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Amelie Burghardt; Frank van Buuren; Zisis Dimitriadis; Tim Grübbel; Hubert Seggewiss; Smita Scholtz; Dieter Horstkotte; Lothar Faber
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

6.  Medical therapy versus interventional therapy in hypertropic obstructive cardiomyopathy.

Authors:  Hubert Seggewiss
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

Review 7.  Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

8.  Percutaneous transluminal radiofrequency closure of the coronary artery in animal studies.

Authors:  Chenyun Zhang; Wei Yi; Yunchang Cai; Shounian Fang; Xinan Jiang; Anzhi Wen; Qiang Wu
Journal:  Exp Ther Med       Date:  2013-08-16       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.